Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia : An-Open Label, Add-On, Pilot Study Shelef A., Barak Y., Berger U., Paleacu D., Tadger S., Plopsky I., Baruch Y. Journal of Alzheimer's Disease, 2016, 51, 1, 15-19. DOI: 10.3233/JAD-150915 BACKGROUND : Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD). OBJECTIVE : To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD). METHODS : Eleven AD patients were recruited to an open label, 4 weeks, prospective trial. RESULTS : Ten patients completed the trial. Significant reduction [...]
Lire la suiteAmyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids Antonio Currais, Oswald Quehenberger, Aaron M Armando, Daniel Daugherty, Pam Maher and David Schubert NPJ, Aging and Mechanisms of Disease, 2016, 2, 16012; doi:10.1038/npjamd.2016.12; published online 23 June 2016 Nature Partner Journals; www.nature.com/npjamd Abstract : The beta amyloid (Aβ) and other aggregating proteins in the brain increase with age and are frequently found within neurons. The mechanistic relationship between intracellular amyloid, aging and neurodegeneration is not, however, well understood. We use a proteotoxicity model based upon the inducible expression of Aβ in a human central nervous system nerve cell line to characterize a distinct form of nerve [...]
Lire la suiteMedical Marijuana MAPS has completed the first-ever clinical trial of smoked marijuana for symptoms of posttraumatic stress disorder (PTSD) in veterans of war. https://maps.org/research/mmj MAPS is working to demonstrate the safety and efficacy of smoked botanical marijuana as a prescription medicine for specific medical uses to the satisfaction of the U.S. Food and Drug Administration. Our efforts to initiate medical marijuana research have been hindered by the National Institute on Drug Abuse (NIDA) and the Drug Enforcement Administration (DEA) since our founding in 1986. NIDA's previous monopoly on the supply of marijuana for research and the DEA's prior refusal to allow researchers to grow [...]
Lire la suiteUsing CBD to Tame a Cannabis High? Small Doses May Have the Opposite Effect Bailey Rahn, February 28, 2019, https://www.leafly.com Posted By Bailey Rahn On February 28, 2019 @ 3:52 pm In Science & Tech https://www.leafly.com/news/science-tech/how-cbd-dose-affects-cannabis-effects/print/ (imaginima/iStock) Take some CBD, they said. You’ll feel less high, they said. This common piece of advice fed to THC-shy consumers can effectively bring someone back down to earth. It works—sometimes. But new research shows there’s likely more nuance in the solution than we initially thought. Scientists found that a high dose of CBD dampened the effects of a THC high, but participants reported a stronger high when combined with low [...]
Lire la suiteNo significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort) Fabienne MARCELLIN, Caroline LIONS, Eric ROSENTHAL, Perrine ROUX, Philippe SOGNI, Linda WITTKOP, Camelia PROTOPOPESCU, Bruno SPIRE, Dominique SALMON-CERON, François DABIS, Maria Patrizia CARRIERI, & HEPAVIH ANRS CO13 STUDY GROUP (10Paris Descartes University, Paris, France) Drug and Alcohol Review (2016) DOI: 10.1111/dar.12398 Abstract : Introduction and Aims. Despite cannabis use being very common in patients co-infected with HIV and hepatitis C virus (HCV), its effect on these patients’ immune systems remains undocumented. Documenting the potential effect of cannabis use on HIV immunological markers [...]
Lire la suiteAn Update of Current Cannabis-Based Pharmaceuticals in Pain Medicine Ivan Urits, Matthew Borchart, Morgan Hasegawa, Justin Kochanski, Vwaire Orhurhu, Omar Viswanath Pain and Therapy, 2019, https://link.springer.com/article/10.1007/s40122-019-0114-4 https://doi.org/10.6084/m9.figshare.7619327 ABSTRACT : Cannabis users have long reported therapeutic properties of the plant for a variety of conditions, some of which include nausea, emesis, seizures, cancer, neurogenic diseases and pain control. Research has elucidated many cannabinoid pharmacodynamic and pharmacokinetic properties, expanding the potential use of cannabinoids as a medical therapy. Due to the inconsistent delivery and control of the active components involved with smoking, pharmaceutical companies are investigating and prioritizing routes other than smoke inhalation for therapeutic use of cannabinoids. In [...]
Lire la suiteTherapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Evan C. Rosenberg, Pabitra H. Patra, and Benjamin J. Whalley Epilepsy & Behavior, 2017 May ; 70(Pt B), 319–327 PMID : 28190698 PMCID : PMC5651410 DOI : 10.1016/j.yebeh.2016.11.006 Abstract : The isolation and identification of the discrete plant cannabinoids in marijuana revived interest in analyzing historical therapeutic claims made for cannabis in clinical case studies and anecdotes. In particular, sources as old as the 11th and 15th centuries claimed efficacy for crude marijuana extracts in the treatment of convulsive disorders, prompting a particularly active area of preclinical research into [...]
Lire la suiteThe dual neuroprotective– neurotoxic profile of cannabinoid drugs Yosef Sarne, Fadi Asaf, Miriam Fishbein, Mikhal Gafni and Ora Keren British Journal of Pharmacology, 2011, 163, 1391–1401 DOI:10.1111/j.1476-5381.2011.01280.x www.brjpharmacol.org Abstract : Extensive in vitro and in vivo studies have shown that cannabinoid drugs have neuroprotective properties and suggested that the endocannabinoid system may be involved in endogenous neuroprotective mechanisms. On the other hand, neurotoxic effects of cannabinoids in vitro and in vivo were also described. Several possible explanations for these dual, opposite effects of cannabinoids on cellular fate were suggested, and it is conceivable that various factors may determine the final outcome of the cannabinoid effect in vivo. [...]
Lire la suiteTaming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects Ethan B Russo British Journal of Pharmacology, 2011, 163, 7, 1344–1364. doi:10.1111/j.1476-5381.2011.01238.x Abstract Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromene, exert additional effects of therapeutic interest. Innovative conventional plant breeding has yielded cannabis chemotypes expressing high titres of each component for future study. This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene [...]
Lire la suiteAnti-excitotoxic effects of cannabidiol are partly mediated by enhancement of NCX2 and NCX3 expression in animal model of cerebral ischemia Sepideh Khaksar, Mohammad Reza Bigdeli European Journal of Pharmacology, 2017, 794, 270-279 DOI : 10.1016/j.ejphar.2016.11.011 A B S T R A C T Excitotoxicity and imbalance of sodium and calcium homeostasis trigger pathophysiologic processes in cerebral ischemia which can accelerate neuronal death. Neuroprotective role of cannabidiol (CBD), one of the main nonpsychoactive phytocannabinoids of the cannabis plant, has attracted attention of many researchers in the neurodegenerative diseases studies. The present investigation was designed to determine whether cannabidiol can alleviate the severity of ischemic damages and [...]
Lire la suite